WO2005087754A1 - Substituted morpholine and thiomorpholine derivatives - Google Patents

Substituted morpholine and thiomorpholine derivatives Download PDF

Info

Publication number
WO2005087754A1
WO2005087754A1 PCT/DK2005/000159 DK2005000159W WO2005087754A1 WO 2005087754 A1 WO2005087754 A1 WO 2005087754A1 DK 2005000159 W DK2005000159 W DK 2005000159W WO 2005087754 A1 WO2005087754 A1 WO 2005087754A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
morpholin
acetamide
dimethyl
alk
Prior art date
Application number
PCT/DK2005/000159
Other languages
English (en)
French (fr)
Inventor
Christian WENZEL TORNØE
Mario Rottländer
Nikolay Khanzhin
Andreas RITZÈN
William Patrick Watson
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005087754(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA200601686A priority Critical patent/EA015120B1/ru
Priority to RSP-2008/0412A priority patent/RS50606B/sr
Priority to KR1020127029156A priority patent/KR20120136422A/ko
Priority to CA2559397A priority patent/CA2559397C/en
Priority to DE602005007474T priority patent/DE602005007474D1/de
Priority to AU2005221762A priority patent/AU2005221762B2/en
Priority to KR1020067018688A priority patent/KR101411204B1/ko
Priority to PL05706819T priority patent/PL1727809T3/pl
Priority to DK05706819T priority patent/DK1727809T3/da
Priority to BRPI0508570A priority patent/BRPI0508570B8/pt
Priority to SI200530344T priority patent/SI1727809T1/sl
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to EP05706819A priority patent/EP1727809B8/en
Priority to NZ549133A priority patent/NZ549133A/en
Priority to JP2007502191A priority patent/JP5006184B2/ja
Publication of WO2005087754A1 publication Critical patent/WO2005087754A1/en
Priority to US11/314,802 priority patent/US7501414B2/en
Priority to ZA2006/07286A priority patent/ZA200607286B/en
Priority to IL177859A priority patent/IL177859A/en
Priority to EGNA2006000856 priority patent/EG25344A/xx
Priority to NO20064599A priority patent/NO337161B1/no
Priority to US12/361,404 priority patent/US20090143369A1/en
Priority to US12/361,509 priority patent/US7632835B2/en
Priority to US12/611,249 priority patent/US8012962B2/en
Priority to US12/612,727 priority patent/US7812023B2/en
Priority to US13/192,833 priority patent/US8299075B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PCT/DK2005/000159 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives WO2005087754A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
EP05706819A EP1727809B8 (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives
NZ549133A NZ549133A (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives
RSP-2008/0412A RS50606B (sr) 2004-03-12 2005-03-09 Supstituisani morfolin i tiomorfolin derivati
JP2007502191A JP5006184B2 (ja) 2004-03-12 2005-03-09 置換されたモルホリンおよびチオモルホリン誘導体
DE602005007474T DE602005007474D1 (en) 2004-03-12 2005-03-09 Substituierte morpholin- und thiomorpholinderivate
AU2005221762A AU2005221762B2 (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives
KR1020067018688A KR101411204B1 (ko) 2004-03-12 2005-03-09 치환된 모르폴린 및 티오모르폴린 유도체
PL05706819T PL1727809T3 (pl) 2004-03-12 2005-03-09 Podstawione morfolinowe i tiomorfolinowe pochodne
DK05706819T DK1727809T3 (da) 2004-03-12 2005-03-09 Substituerede morpholin og thiomorpholin derivater
BRPI0508570A BRPI0508570B8 (pt) 2004-03-12 2005-03-09 composto, composição farmacêutica, e, uso da mesma
SI200530344T SI1727809T1 (sl) 2004-03-12 2005-03-09 SUBSTITUIRANI DERIVATI MORFOLINA in TIOMORFOLINA
EA200601686A EA015120B1 (ru) 2004-03-12 2005-03-09 Замещенные производные морфолина и тиоморфолина
CA2559397A CA2559397C (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives
KR1020127029156A KR20120136422A (ko) 2004-03-12 2005-03-09 치환된 모르폴린 및 티오모르폴린 유도체
US11/314,802 US7501414B2 (en) 2004-03-12 2005-12-21 Substituted morpholine and thiomorpholine derivatives
ZA2006/07286A ZA200607286B (en) 2004-03-12 2006-08-31 Substituted morpholine and thiomorpholine derivatives
IL177859A IL177859A (en) 2004-03-12 2006-09-03 Transformed morpholine and thymorpholine derivatives
EGNA2006000856 EG25344A (en) 2004-03-12 2006-09-12 Substituted morpholine and thiomorpholine derivatives.
NO20064599A NO337161B1 (no) 2004-03-12 2006-10-10 Substituerte morfolin- og tiomorfolinderivater
US12/361,404 US20090143369A1 (en) 2004-03-12 2009-01-28 Methods of using substituted morpholine and thiomorpholine derivatives
US12/361,509 US7632835B2 (en) 2004-03-12 2009-01-28 Substituted morpholine and thiomorpholine derivatives
US12/611,249 US8012962B2 (en) 2004-03-12 2009-11-03 Substituted thiomorpholine derivatives
US12/612,727 US7812023B2 (en) 2004-03-12 2009-11-05 Methods of using substituted morpholine derivatives
US13/192,833 US8299075B2 (en) 2004-03-12 2011-07-28 Substituted thiomorpholine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12
US60/552,574 2004-03-12
DKPA200400412 2004-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/314,802 Continuation US7501414B2 (en) 2004-03-12 2005-12-21 Substituted morpholine and thiomorpholine derivatives

Publications (1)

Publication Number Publication Date
WO2005087754A1 true WO2005087754A1 (en) 2005-09-22

Family

ID=37730781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000159 WO2005087754A1 (en) 2004-03-12 2005-03-09 Substituted morpholine and thiomorpholine derivatives

Country Status (32)

Country Link
US (6) US7501414B2 (US08012962-20110906-C00001.png)
EP (3) EP2138487A1 (US08012962-20110906-C00001.png)
JP (1) JP5006184B2 (US08012962-20110906-C00001.png)
KR (2) KR101411204B1 (US08012962-20110906-C00001.png)
CN (2) CN1930138A (US08012962-20110906-C00001.png)
AR (1) AR049784A1 (US08012962-20110906-C00001.png)
AT (2) ATE398112T1 (US08012962-20110906-C00001.png)
AU (1) AU2005221762B2 (US08012962-20110906-C00001.png)
BR (1) BRPI0508570B8 (US08012962-20110906-C00001.png)
CA (1) CA2559397C (US08012962-20110906-C00001.png)
CO (1) CO5721001A2 (US08012962-20110906-C00001.png)
CY (2) CY1110392T1 (US08012962-20110906-C00001.png)
DE (2) DE602005016849D1 (US08012962-20110906-C00001.png)
DK (2) DK1727809T3 (US08012962-20110906-C00001.png)
EA (1) EA015120B1 (US08012962-20110906-C00001.png)
EG (1) EG25344A (US08012962-20110906-C00001.png)
ES (2) ES2306087T3 (US08012962-20110906-C00001.png)
HK (1) HK1172618A1 (US08012962-20110906-C00001.png)
HR (1) HRP20090685T1 (US08012962-20110906-C00001.png)
IL (1) IL177859A (US08012962-20110906-C00001.png)
MY (2) MY147786A (US08012962-20110906-C00001.png)
NO (1) NO337161B1 (US08012962-20110906-C00001.png)
NZ (1) NZ549133A (US08012962-20110906-C00001.png)
PL (2) PL1727809T3 (US08012962-20110906-C00001.png)
PT (2) PT1947093E (US08012962-20110906-C00001.png)
RS (2) RS50606B (US08012962-20110906-C00001.png)
SG (1) SG151254A1 (US08012962-20110906-C00001.png)
SI (2) SI1727809T1 (US08012962-20110906-C00001.png)
TW (2) TWI349666B (US08012962-20110906-C00001.png)
UA (2) UA102517C2 (US08012962-20110906-C00001.png)
WO (1) WO2005087754A1 (US08012962-20110906-C00001.png)
ZA (2) ZA200607286B (US08012962-20110906-C00001.png)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
EP1791809A1 (en) * 2004-09-13 2007-06-06 H. Lundbeck A/S Substituted aniline derivatives
WO2007090409A1 (en) * 2006-02-07 2007-08-16 H. Lundbeck A/S Use of kcnq-openers for threating or reducing the symptoms of schizophrenia
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2009015667A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
WO2011026891A1 (en) * 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
WO2010130260A3 (en) * 2009-05-11 2011-06-16 H. Lundbeck A/S Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
EA016244B1 (ru) * 2005-03-03 2012-03-30 Х. Лундбекк А/С Производные замещённых пиридинов
US8293911B2 (en) 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2013060097A1 (zh) 2011-10-25 2013-05-02 中国科学院上海药物研究所 一类可用作kcnq钾通道激动剂的新型化合物、其制备方法和用途
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2016090317A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
WO2022215080A1 (en) * 2021-04-08 2022-10-13 Yeda Research And Development Co. Ltd. A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049444A1 (en) * 1999-08-04 2001-12-06 Mcnaughton-Smith Grant Pyridine-substituted benzanilides as potassium ion channel openers
WO2002049628A2 (en) * 2000-12-20 2002-06-27 Wyeth Methods of treating anxiety disorders
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
AU6645998A (en) * 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
EP1042299A1 (en) * 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
WO1999050255A2 (en) 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6893858B2 (en) 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
AU2001268303A1 (en) 2000-06-11 2001-12-24 Du Pont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
EP1353915A2 (en) * 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic chroman compounds
BR0206513A (pt) * 2001-01-16 2004-01-06 Astrazeneca Ab Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049444A1 (en) * 1999-08-04 2001-12-06 Mcnaughton-Smith Grant Pyridine-substituted benzanilides as potassium ion channel openers
WO2002049628A2 (en) * 2000-12-20 2002-06-27 Wyeth Methods of treating anxiety disorders
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BEILSTEIN BEILSTEIN CROSSFIRE INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, DE; 1993, XP002330358 *
MAIN M J ET AL: "MODULATION OF KCNQ2/3 POTASSIUM CHANNELS BY THE NOVEL ANTICONVULSANT RETIGABINE", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 58, no. 2, August 2000 (2000-08-01), pages 253 - 262, XP000972245, ISSN: 0026-895X *
VERMA M AL, ARCH PHARM (WEINHEIM W GER), vol. 315, no. 7, 1982, pages 358 - 363 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
EP1791809A1 (en) * 2004-09-13 2007-06-06 H. Lundbeck A/S Substituted aniline derivatives
US7601870B2 (en) 2004-09-13 2009-10-13 H. Lundbeck A/S Substituted aniline derivatives
AU2006220130B2 (en) * 2005-03-03 2011-07-28 H. Lundbeck A/S Substituted pyridine derivatives
EA016244B1 (ru) * 2005-03-03 2012-03-30 Х. Лундбекк А/С Производные замещённых пиридинов
CN102276523B (zh) * 2005-03-03 2014-12-10 H.隆德贝克有限公司 取代的吡啶衍生物
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
EP2298766A1 (en) * 2005-03-03 2011-03-23 H. Lundbeck A/S Substituted pyridine derivatives
US8299071B2 (en) 2005-03-03 2012-10-30 H. Lundbeck A/S Substituted pyridine derivatives
US7812020B2 (en) 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
TWI453013B (zh) * 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
EP2554162A1 (en) 2006-02-07 2013-02-06 H. Lundbeck A/S Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia
EA017915B1 (ru) * 2006-02-07 2013-04-30 Х. Лундбекк А/С Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
JP2009525993A (ja) * 2006-02-07 2009-07-16 ハー・ルンドベック・アクチエゼルスカベット 統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法
AU2007214128B2 (en) * 2006-02-07 2012-05-17 H. Lundbeck A/S Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia
WO2007090409A1 (en) * 2006-02-07 2007-08-16 H. Lundbeck A/S Use of kcnq-openers for threating or reducing the symptoms of schizophrenia
US8338487B2 (en) 2006-06-05 2012-12-25 Valeant Pharmaceuticals International, Inc. Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8293911B2 (en) 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2008130616A3 (en) * 2007-04-19 2008-12-18 Schering Corp Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
WO2009015667A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8211918B2 (en) 2007-08-13 2012-07-03 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
JP2010536771A (ja) * 2007-08-13 2010-12-02 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての５−アミノ−４，６−二置換インドールおよび５−アミノ−４，６−二置換インドリンの誘導体
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
AU2010246724B2 (en) * 2009-05-11 2013-03-21 H. Lundbeck A/S Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide
WO2010130260A3 (en) * 2009-05-11 2011-06-16 H. Lundbeck A/S Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2011026891A1 (en) * 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
WO2013060097A1 (zh) 2011-10-25 2013-05-02 中国科学院上海药物研究所 一类可用作kcnq钾通道激动剂的新型化合物、其制备方法和用途
WO2016090317A1 (en) * 2014-12-05 2016-06-09 Aquinnah Pharmaceuticals, Inc. Sulfonamide derivatives, compositions and methods of use in the treatment of neurodegenerative diseases
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
WO2018158256A3 (en) * 2017-02-28 2018-12-13 Acousia Therapeutics Gmbh Novel compounds useful as potassium channel openers
US11034665B2 (en) 2017-02-28 2021-06-15 Acousia Therapeutics Gmbh Compounds useful as potassium channel openers
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
WO2022215080A1 (en) * 2021-04-08 2022-10-13 Yeda Research And Development Co. Ltd. A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
ES2306087T3 (es) 2008-11-01
IL177859A0 (en) 2006-12-31
PT1947093E (pt) 2009-12-22
EP1727809A1 (en) 2006-12-06
SG151254A1 (en) 2009-04-30
NO20064599L (no) 2006-12-08
BRPI0508570A (pt) 2007-08-14
EA200601686A1 (ru) 2007-02-27
US8012962B2 (en) 2011-09-06
ATE398112T1 (de) 2008-07-15
DK1947093T3 (da) 2010-02-01
PT1727809E (pt) 2008-08-13
EP1947093B1 (en) 2009-09-23
DE602005007474D1 (en) 2008-07-24
HK1172618A1 (zh) 2013-04-26
US20100063036A1 (en) 2010-03-11
HRP20090685T1 (hr) 2010-02-28
US20110294787A1 (en) 2011-12-01
UA102517C2 (ru) 2013-07-25
TW200811121A (en) 2008-03-01
EP1727809B1 (en) 2008-06-11
SI1947093T1 (sl) 2010-01-29
RS50606B (sr) 2010-05-07
CA2559397C (en) 2010-08-10
US20060167248A1 (en) 2006-07-27
EG25344A (en) 2011-12-14
KR101411204B1 (ko) 2014-06-23
KR20120136422A (ko) 2012-12-18
US20090137571A1 (en) 2009-05-28
RS51066B (sr) 2010-10-31
NO337161B1 (no) 2016-02-01
CA2559397A1 (en) 2005-09-22
ZA200709718B (en) 2008-09-25
ES2334076T3 (es) 2010-03-04
EP1947093B9 (en) 2010-03-03
ATE443702T1 (de) 2009-10-15
JP5006184B2 (ja) 2012-08-22
CY1109656T1 (el) 2014-08-13
BRPI0508570B8 (pt) 2021-05-25
US7812023B2 (en) 2010-10-12
EA015120B1 (ru) 2011-06-30
CN1930138A (zh) 2007-03-14
US7501414B2 (en) 2009-03-10
MY147786A (en) 2013-01-31
PL1947093T3 (pl) 2010-02-26
US7632835B2 (en) 2009-12-15
TWI349666B (en) 2011-10-01
TWI357901B (en) 2012-02-11
AR049784A1 (es) 2006-09-06
US8299075B2 (en) 2012-10-30
KR20060128004A (ko) 2006-12-13
SI1727809T1 (sl) 2008-10-31
AU2005221762A1 (en) 2005-09-22
PL1727809T3 (pl) 2008-11-28
TW200533359A (en) 2005-10-16
CN102516204B (zh) 2016-01-20
UA90670C2 (en) 2010-05-25
DK1727809T3 (da) 2008-09-29
CO5721001A2 (es) 2007-01-31
CN102516204A (zh) 2012-06-27
JP2007528880A (ja) 2007-10-18
US20090143369A1 (en) 2009-06-04
DE602005016849D1 (de) 2009-11-05
MY143698A (en) 2011-06-30
NZ549133A (en) 2010-09-30
EP2138487A1 (en) 2009-12-30
CY1110392T1 (el) 2015-04-29
AU2005221762B2 (en) 2011-06-09
US20100063033A1 (en) 2010-03-11
IL177859A (en) 2013-02-28
ZA200607286B (en) 2008-04-30
EP1727809B8 (en) 2008-10-29
BRPI0508570B1 (pt) 2018-11-21
EP1947093A1 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
EP1727809B8 (en) Substituted morpholine and thiomorpholine derivatives
AU2006220130B2 (en) Substituted pyridine derivatives
EP1791809A1 (en) Substituted aniline derivatives
US20060264496A1 (en) Substituted indoline and indole derivatives
MXPA06010329A (en) Substituted morpholine and thiomorpholine derivatives
NZ541999A (en) Substituted indoline and indole derivatives
NZ556613A (en) Substituted pyridine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11314802

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11314802

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 549133

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006501675

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006/07286

Country of ref document: ZA

Ref document number: 200607286

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 177859

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2559397

Country of ref document: CA

Ref document number: PA/a/2006/010329

Country of ref document: MX

Ref document number: 200580007885.7

Country of ref document: CN

Ref document number: 2007502191

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005221762

Country of ref document: AU

Ref document number: 1020067018688

Country of ref document: KR

Ref document number: 06091597

Country of ref document: CO

Ref document number: 3297/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005706819

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200601599

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2005221762

Country of ref document: AU

Date of ref document: 20050309

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005221762

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200601686

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005706819

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067018688

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0508570

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2005706819

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2008/0412

Country of ref document: RS